• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,664.21 -999.79
( -1.29%)
Global Indices
Nasdaq
49,249.13 -82.20
(-0.17%)
Dow Jones
7,185.72 56.32
(0.79%)
Hang Seng
59,744.07 603.84
(1.02%)
Nikkei 225
10,387.94 -69.07
(-0.66%)
Forex
USD-INR
94.05 0.29
(0.31%)
EUR-INR
109.99 0.01
(0.01%)
GBP-INR
126.84 0.17
(0.14%)
JPY-INR
0.59 0.00
(0.16%)

EQUITY - MARKET SCREENER

Transcorp International Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
532410
INE330E01023
16.7885326
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
19.85
84.36
EPS(TTM)
Face Value()
Div & Yield %
1.33
2
2.27
 

apollo pipes ltd
Lupin launches diabetes drug in U.S. after FDA nod
Apr 22,2026
The product is bioequivalent to Xigduo XR and will be marketed for the same indications as per the approved labeling.

Dapagliflozin and Metformin Hydrochloride is a combination medication used to improve glycemic control in adults with type 2 diabetes

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The counter shed 0.10% to end at Rs 2,309.45 on the BSE.